Silence Therapeutics reported a sharply higher first quarter for calendar 2024 (QQ1 2024) with revenue of £12.406 million, up 9.1% year-over-year and a striking sequential rise from the prior quarter (Q4 2023 revenue £2.099 million). The gross margin remained robust at 82.2%, delivering gross profit of £10.193 million on the quarter. However, the company posted an operating loss of £4.156 million and a net loss of £1.876 million, with earnings per share of £-0.0426. The quarter benefited from a significant net cash inflow from financing activities (£105.6 million), primarily driven by common equity issuance (£112.1 million), which lifted end-period cash and short-term investments to £152.8 million and left Silence with a substantial net cash position (net debt of £-112.8 million).
The results underscore a biotech company transitioning from early-stage investment phase toward a more mature pipeline development posture. The revenue spike appears to be driven by one-off or milestone-related activity rather than a steady-state revenue stream, given the scale of the sequential jump and the absence of a corresponding rise in cost of revenue. Management commentary (where available in the transcripts) typically emphasizes progress on high-potential RNAi programs and ongoing collaboration engagements (e.g., with AstraZeneca, Mallinckrodt, Hansoh) as the longer-term driver of value. In the near term, Silence maintains substantial liquidity runway to fund R&D and platform expansion while monitoring milestone-based monetization from collaborations. This sets up an investment case anchored in pipeline progress and balance-sheet resilience, albeit with continued near-term profitability challenges until meaningful product-phase milestones are achieved.